title: [Study on mechanism of bortezomib inducing peripheral neuropathy and the reversing effect of reduced glutathione].
abstract: OBJECTIVE
  To study the mechanism of bortezomib inducing peripheral neuropathy and the reversing affection of reduced glutathione.
  
  
  METHODS
  Female Wistar rats were randomly divided into three groups. Group 1, treatment with bortezomib; Group 2, treatment with bortezomib and reduced glutathione; Group 3, saline control group. Drugs were administrated on the 1st, 4th, 7th and 11th day for the three groups. The amorphous of sciatic nerve and dorsal root ganglion (DRG) were observed by electron microscope on 14th and 42nd day. On 14th day, laser confocal microscopy was used to detect reactive oxygen species (ROS) of DRG neuron obtained from the rats by treated with DCFH-DA after primary culture.
  
  
  RESULTS
  On 14th day, morphology of sciatic nerve and DRG changed in both group 1 and 2. On 42nd day, the amorphous became normally in group 1. On 14th day, ROS releasing from DRG neuron was increased obviously in group 1 (P < 0.01), while decreased in both group 2 and 3, and the difference between the latter two groups had no statistical significance (P = 0.210).
  
  
  CONCLUSIONS
  Releasing ROS to injure mitochondrion and endoplasmic reticulum maybe involved in bortezomib induced peripheral neuropathy. Although reduced glutathione can inhibit ROS release, it has no obviously reversal effect for peripheral neuropathy.
authors.affiliation: Hematology Malignancy Treatment Center, Sheng Jing Hospital, China Medical University, Shenyang 110022, China.
authors.forename: Hong-tao
authors.initials: HT
authors.lastname: Wang
authors.forename: Zhuo-gang
authors.initials: ZG
authors.lastname: Liu
authors.forename: Wei
authors.initials: W
authors.lastname: Yang
authors.forename: Ai-jun
authors.initials: AJ
authors.lastname: Liao
authors.forename: Rong
authors.initials: R
authors.lastname: Zhang
authors.forename: Bin
authors.initials: B
authors.lastname: Wu
authors.forename: Hui-han
authors.initials: HH
authors.lastname: Wang
authors.forename: Kun
authors.initials: K
authors.lastname: Yao
authors.forename: Ying-chun
authors.initials: YC
authors.lastname: Li
mesh_terms: D000818:Animals; D001897:Boronic Acids / Q000009:adverse effects; D000069286:Bortezomib; D005260:Female; D005978:Glutathione / Q000627:therapeutic use*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000378:metabolism* / Q000517:prevention & control*; D011719:Pyrazines / Q000009:adverse effects; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000378:metabolism
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D017382:Reactive Oxygen Species; D000069286:Bortezomib; D005978:Glutathione